Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ERK5-IN-4 (compound 34b) is a powerful and specific inhibitor of extracellular signal-related kinase 5 (ERK5) activity. It effectively inhibits both the full-length ERK5 and the truncated ERK5 (ERK5 ΔTAD) kinase activity in HEK293 cells with IC50 values of 77 nM and 300 nM, respectively [1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | ERK5-IN-4 (compound 34b) is a powerful and specific inhibitor of extracellular signal-related kinase 5 (ERK5) activity. It effectively inhibits both the full-length ERK5 and the truncated ERK5 (ERK5 ΔTAD) kinase activity in HEK293 cells with IC50 values of 77 nM and 300 nM, respectively [1]. |
体外活性 | ERK5-IN-4 (compound 34b) is selective against MAP3K, p38 (IC 50 >30 μM) and BRD4 (IC 50 >20 μM), in contrast to many reported ERK5 inhibitors [1]. ERK5-IN-4 (0-100 μM; 72 h) suppresses ERK5 kinase activity in HEK293 cells and (0-1 μM; 72 h) induces paradoxical activation of ERK5 transcriptional activity, thus resulting in C-terminal transcriptional activation domain (TAD) separated from the nuclear localization sequence (NLS) and results ERK5 nuclear translocation [1]. ERK5-IN-4 inhibits cancer cells with GI 50 of 19.6 μM (HEK293), 22.3 μM (A498), 25 μM (SJSA-1), 26.6 μM (MDA-MB-231) following a 72 h incubation [1]. ERK5-IN-4 exhibits kinome selectivity K d of 1.2 μM, 0.29 μM, 0.046 μM, 0.061 μM, 0.18 μM, 0.38 μM, 1.3 μM, 0.42 μM, 0.22 μM, 2.8 μM against ABL1-nonphosphorylated, AURKA, CSF1R, DCAMKL1 (DCLK1), ERK5 (MAPK7), FGFR1, JAK3 (JH1domain-catalytic), KIT, LRRK2, MEK5 (MAP2K5) [1]. Western Blot Analysis [1] Cell Line: HeLa cells Concentration: 0.01, 0.03, 0.1, 0.3, 1, 3 μM Incubation Time: 1 h Result: Resulted upper phospho-ERK5 band with EGF stimulation and inhibition. |
体内活性 | ERK5-IN-4 (compound 34b) (p.o.; 10 mg/kg) has low clearance and an oral bioavailability of 42% in the mouse [1]. Animal Model: Pharmacokinetic Parameters for ERK5-IN-4 [1] Dosage: Administration: Result: Route Dose (mg/kg) Cl (mL/min/kg) V d (L/kg) t 1/2 (min) BA (%) i.v. or p.o. 10 14 0.6 80 42 |
分子量 | 381.19 |
分子式 | C16H11Cl2FN4O2 |
CAS No. | 1888305-17-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ERK5-IN-4 1888305-17-6 Inhibitor inhibitor inhibit